Small‐molecule protein–protein interaction inhibitors: Therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139 · see citing works

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484 · see citing works

How to improve R&D productivity: the pharmaceutical industry's grand challenge

Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · see citing works

How many drug targets are there?

Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505 · see citing works

Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412

Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 2× · see citing works

Anatomy of hot spots in protein interfaces

Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988 · see citing works

Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,963 · see citing works

Protein Therapeutics: A Summary and Pharmacological Classification

Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 1,913 · see citing works

Ligand efficiency: a useful metric for lead selection

Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,895 · see citing works

Small-molecule inhibitors of protein–protein interactions: progressing towards the dream

Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · see citing works

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Dorr, P. K., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M. J., Mori, J., Rickett, G., Smith‐Burchnell, C., Napier, C. M., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,154 · see citing works

Estimating the size of the human interactome

Stumpf, M. P. H., Thorne, T., de Silva, E., Stewart, R., An, H. J., Lappé, M., & Wiuf, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708078105 · Cited by 827 · see citing works

Small-Molecule Inhibition of TNF-α

He, M. M., Stroustrup, A., Oslob, J. D., Flanagan, W. M., Braisted, A. C., Whitty, A., Cancilla, M. T., Wang, J., Lugovskoy, A. A., Yoburn, J. C., et al. (2005) · Science · doi:10.1126/science.1116304 · Cited by 626 · see citing works

Anti-TNF-α therapies: the next generation

Palladino, M. A., Bahjat, F. R., Theodorakis, E. A., & Moldawer, L. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1175 · Cited by 579 · see citing works

Privileged Molecules for Protein Binding Identified from NMR-Based Screening

Hajduk, P. J., Bures, M. G., Praestgaard, J., & Fesik, S. W. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000164q · Cited by 353 · see citing works

Predicting druggable binding sites at the protein–protein interface

Fuller, J. C., Burgoyne, N. J., & Jackson, R. M. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.009 · Cited by 311 · see citing works

Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins

Park, C., Bruncko, M., Adickes, J., Bauch, J. L., Ding, H., Kunzer, A. R., Marsh, K. C., Nimmer, P. M., Shoemaker, A. R., Song, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800669s · Cited by 301 · see citing works

Modulation of Protein–Protein Interactions with Small Organic Molecules

Berg, T. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200558 · Cited by 292 · see citing works

Predicting protein druggability

Hajduk, P. J., Huth, J. R., & Tse, C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03624-x · Cited by 289 · see citing works

Fragment-Based Drug Design: How Big Is Too Big?

Hajduk, P. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060511h · Cited by 269 · see citing works

Drugs, leads, and drug-likeness: an analysis of some recently launched drugs

Proudfoot, J. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00244-5 · Cited by 252 · see citing works

Small Molecule Disruption of G Protein βγ Subunit Signaling Inhibits Neutrophil Chemotaxis and Inflammation

Lehmann, D. M., Seneviratne, A. M. P. B., & Smrcka, A. V. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.041780 · Cited by 234 · see citing works

Differential Targeting of Gßγ-Subunit Signaling with Small Molecules

Bonacci, T. M., Mathews, J. L., Yuan, C., Lehmann, D. M., Malik, S., Wu, D., Font, J. L., Bidlack, J. M., & Smrcka, A. V. (2006) · Science · doi:10.1126/science.1120378 · Cited by 231 · see citing works

Protein–protein interactions as targets for small molecule drug discovery

Fry, D. C. (2006) · Biopolymers · doi:10.1002/bip.20608 · Cited by 203 · see citing works

Rationalizing the chemical space of protein–protein interaction inhibitors

Spérandio, O., Reynès, C., Camproux, A., & Villoutreix, B. O. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.007 · Cited by 202 · see citing works

Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles

Blazer, L. L., & Neubig, R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.151 · Cited by 197 · see citing works

The road less traveled: modulating signal transduction enzymes by inhibiting their protein–protein interactions

Arkin, M. R., & Whitty, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.125 · Cited by 190 · see citing works

Between a rock and a hard place?

Whitty, A., & Kumaravel, G. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0306-112 · Cited by 170 · see citing works

The role of molecular size in ligand efficiency

Reynolds, C. H., Bembenek, S. D., & Tounge, B. A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.038 · Cited by 168 · see citing works

Atomic Interactions and Profile of Small Molecules Disrupting Protein–Protein Interfaces: the TIMBAL Database

Higueruelo, A. P., Schreyer, A. M., Bickerton, G. R., Pitt, W. R., Groom, C. R., & Blundell, T. L. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00889.x · Cited by 155 · see citing works

KFC Server: interactive forecasting of protein interaction hot spots

Darnell, S. J., LeGault, L., & Mitchell, J. C. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn346 · Cited by 152 · see citing works

Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α

Carter, P. H., Scherle, P., Muckelbauer, J. A., Voss, M. E., Liu, R., Thompson, L. A., Tebben, A. J., Solomon, K. A., Lo, Y. C., Li, Z., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211178398 · Cited by 142 · see citing works

Identification of Small-Molecule Inhibitors of RGS4 Using a High-Throughput Flow Cytometry Protein Interaction Assay

Roman, D. L., Talbot, J. N., Roof, R. A., Sunahara, R. K., Traynor, J. R., & Neubig, R. R. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.028670 · Cited by 135 · see citing works

Small molecular weight protein–protein interaction antagonists—an insurmountable challenge?

Dömling, A. S. S. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.04.603 · Cited by 128 · see citing works

Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database

Bourgeas, R., Basse, M.-J., Morelli, X., & Roche, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009598 · Cited by 126 · see citing works

Designing Focused Chemical Libraries Enriched in Protein-Protein Interaction Inhibitors using Machine-Learning Methods

Reynès, C., Host, H., Camproux, A., Laconde, G., Leroux, F., Mazars, A., Deprez, B. P., Fåhræus, R., Villoutreix, B. O., & Spérandio, O. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000695 · Cited by 119 · see citing works

Integrating Fragment Assembly and Biophysical Methods in the Chemical Advancement of Small-Molecule Antagonists of IL-2: An Approach for Inhibiting Protein−Protein Interactions

Raimundo, B. C., Oslob, J. D., Braisted, A. C., Hyde, J., McDowell, R. S., Randal, M., Waal, N. D., Wilkinson, J., Yu, C. H., & Arkin, M. R. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049967u · Cited by 86 · see citing works

Discovery of a novel small molecule binding site of human survivin

Wendt, M. D., Sun, C. C., Kunzer, A. R., Sauer, D. R., Sarris, K., Hoff, E. D., Yu, L. P., Nettesheim, D. G., Chen, J., Jin, S. S., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.042 · Cited by 82 · see citing works

The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias

Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0337 · Cited by 78 · see citing works

Drug-Like Inhibitors of Protein-Protein Interactions: A Structural Examination of Effective Protein Mimicry

Fry, D. C. (2008) · Current Protein and Peptide Science · doi:10.2174/138920308784533989 · Cited by 76 · see citing works

Prediction of Protein−Protein Interaction Inhibitors by Chemoinformatics and Machine Learning Methods

Neugebauer, A., Hartmann, R. W., & Klein, C. D. P. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070533j · Cited by 75 · see citing works

Small-molecule inhibitors of the p53 suppressor HDM2: have protein–protein interactions come of age as drug targets?

Fischer, P. M., & Lane, D. P. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.011 · Cited by 70 · see citing works

London's disastrous drug trial has serious side effects for research

Wadman, M. (2006) · Nature · doi:10.1038/440388a · Cited by 60 · see citing works

Identification of small-molecule inhibitors of the JIP–JNK interaction

Chen, T. X., Kablaoui, N. M., Little, J., Timofeevski, S. L., Tschantz, W. R., Chen, P., Feng, J., Charlton, M. E., Stanton, R. V., & Bauer, P. H. (2009) · Biochemical Journal · doi:10.1042/bj20081899 · Cited by 55 · see citing works

The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Gα-interaction face

Kimple, A. J., Willard, F. S., Giguère, P. M., Johnston, C. A., Mocanu, V., & Siderovski, D. P. (2007) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.06.002 · Cited by 50 · see citing works

Glucocorticoid receptor binding: A biphasic dependence on molecular size as revealed by the bilinear LinBiExp model

Buchwald, P. (2007) · Steroids · doi:10.1016/j.steroids.2007.10.001 · Cited by 40 · see citing works

Small-molecule costimulatory blockade: organic dye inhibitors of the CD40–CD154 interaction

Margolles‐Clark, E., Umland, O., Kenyon, N. S., Ricordi, C., & Buchwald, P. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0519-3 · Cited by 35 · see citing works

Molecular Organization of the Complex between the Muscarinic M3 Receptor and the Regulator of G Protein Signaling, Gβ 5 −RGS7

Sandiford, S. L., Wang, Q., Levay, K., Buchwald, P., & Slepak, V. Z. (2010) · Biochemistry · doi:10.1021/bi100080p · Cited by 21 · see citing works

Research Article: Effective and Specific Inhibition of the CD40–CD154 Costimulatory Interaction by a Naphthalenesulphonic Acid Derivative

Margolles‐Clark, E., Kenyon, N. S., Ricordi, C., & Buchwald, P. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01014.x · Cited by 17 · see citing works

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891 · see citing works

Targeting protein–protein interactions as an anticancer strategy

Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401 · see citing works

How proteins bind macrocycles

Villar, E. A., Beglov, D., Chennamadhavuni, S., Porco, J. A. J., Kozakov, D., Vajda, S., & Whitty, A. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1584 · Cited by 401 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Peptide therapeutics: Targeting the undruggable space

Tsomaia, N. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.014 · Cited by 348 · see citing works

Getting pharmaceutical R&D back on target

Bunnage, M. E. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.581 · Cited by 258 · see citing works

Chemical and structural lessons from recent successes in protein–protein interaction inhibition (2P2I)

Morelli, X., Bourgeas, R., & Roche, P. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.024 · Cited by 223 · see citing works

Cyclic Peptides as Drugs for Intracellular Targets: The Next Frontier in Peptide Therapeutic Development

Buckton, L. K., Rahimi, M. N., & McAlpine, S. R. (2020) · Chemistry - A European Journal · doi:10.1002/chem.201905385 · Cited by 194 · see citing works

Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells – Role of Anchored Protein Kinase A Signaling Units

Wehbi, V. L., & Taskén, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00222 · Cited by 182 · see citing works

State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors

Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165 · see citing works

Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein–Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2

Bojadzic, D., Alcazar, O., Chen, J., Chuang, S.-T., Capcha, J. M. C., Shehadeh, L. A., & Buchwald, P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00070 · Cited by 143 · see citing works

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

Liu, H., Zhao, Z., Zhang, L., Li, Y., Jain, A., Barve, A. J., Jin, W., Liu, Y., Fetse, J., & Cheng, K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0705-y · Cited by 133 · see citing works

Drugging the undruggable: Transcription therapy for cancer

Yan, C., & Higgins, P. J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.11.002 · Cited by 121 · see citing works

Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease

Bulic, B., Pickhardt, M., & Mandelkow�, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017317 · Cited by 116 · see citing works

Drug‐Like ProteinProtein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology

Villoutreix, B. O., Kuenemann, M. A., Poyet, J., Bruzzoni‐Giovanelli, H., Labbé, C. M., Lagorce, D., Spérandio, O., & Miteva, M. A. (2014) · Molecular Informatics · doi:10.1002/minf.201400040 · Cited by 114 · see citing works

Targeting Protein–Protein Interactions and Fragment-Based Drug Discovery

Valkov, E., Sharpe, T., Marsh, M., Greive, S., & Hyvönen, M. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_265 · Cited by 107 · see citing works

Small Molecule AKAP-Protein Kinase A (PKA) Interaction Disruptors That Activate PKA Interfere with Compartmentalized cAMP Signaling in Cardiac Myocytes

Frank, C., Szaszák, M., Friedl, S., Drewianka, S., Lorenz, D., Gonçalves, A. C. D. C., Furkert, J., Vargas, C., Schmieder, P., Götz, F. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160614 · Cited by 107 · see citing works

High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein Interaction

He, S., Senter, T. J., Pollock, J., Han, C., Upadhyay, S. K., Purohit, T., Gogliotti, R. D., Lindsley, C. W., Cierpicki, T., Stauffer, S. R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401868d · Cited by 99 · see citing works

Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics

Warrier, N. M., Agarwal, P., & Kumar, P. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-09995-4 · Cited by 92 · see citing works

Surfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI Inhibitors

Sable, R. V., & Jois, S. D. S. (2015) · Molecules · doi:10.3390/molecules200611569 · Cited by 90 · see citing works

2P2Idb v2: update of a structural database dedicated to orthosteric modulation of protein–protein interactions

Basse, M.-J., Betzi, S., Morelli, X., & Roche, P. (2016) · Database · doi:10.1093/database/baw007 · Cited by 83 · see citing works

HIV-1 capsid inhibitors as antiretroviral agents

Thenin-Houssier, S., & Valente, S. (2016) · Current HIV Research · doi:10.2174/1570162x14999160224103555 · Cited by 75 · see citing works

Toward Small-Molecule Inhibition of Protein–Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions

Bojadzic, D., & Buchwald, P. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180531092503 · Cited by 81 · see citing works

Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein–Protein Interaction between Menin and Mixed Lineage Leukemia (MLL)

Borkin, D., Pollock, J., Kempińska, K., Purohit, T., Li, X., Wen, B., Zhao, T., Miao, H., Shukla, S., He, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01305 · Cited by 61 · see citing works

The food colorant erythrosine is a promiscuous protein–protein interaction inhibitor

Ganesan, L., Margolles‐Clark, E., Song, Y., & Buchwald, P. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.12.020 · Cited by 74 · see citing works

Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)

Melagraki, G., Ntougkos, E., Rinotas, V. E., Papaneophytou, C. P., Leonis, G., Mavromoustakos, T., Kontopidis, G. A., Douni, E. K., Afantitis, A., & Kollias, G. A. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005372 · Cited by 69 · see citing works

Complexity of Blocking Bivalent Protein–Protein Interactions: Development of a Highly Potent Inhibitor of the Menin–Mixed-Lineage Leukemia Interaction

Borkin, D., Kłossowski, S., Pollock, J., Miao, H. Z., Linhares, B. M., Kempińska, K., Jin, Z., Purohit, T., Wen, B., He, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00071 · Cited by 65 · see citing works

The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response

Seifert, L. L., Si, C., Saha, D., Sadic, M., de Vries, M., Ballentine, S., Briley, A., Wang, G., Valero-Jimenez, A. M., Mohamed, A., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007634 · Cited by 56 · see citing works

Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate

Anand, U., Bandyopadhyay, A., Jha, N. K., de la Lastra, J. M. P., & Dey, A. (2022) · BioFactors · doi:10.1002/biof.1913 · Cited by 62 · see citing works

In silico design of low molecular weight protein–protein interaction inhibitors: Overall concept and recent advances

Kuenemann, M. A., Spérandio, O., Labbé, C. M., Lagorce, D., Miteva, M. A., & Villoutreix, B. O. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.02.006 · Cited by 61 · see citing works

Computational approaches for the design of modulators targeting protein-protein interactions

Rehman, A. U., Khurshid, B., Ali, Y., Rasheed, S., Wadood, A., Ng, H. L., Chen, H., Wei, Z., Luo, R., & Zhang, J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2171396 · Cited by 62 · see citing works

Taking Aim at the Undruggable

Coleman, N., & Rodon, J. A. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_325885 · Cited by 58 · see citing works

The Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells—a Potential Target for Pharmacological Intervention in Cardiovascular Diseases

Vukićević, T., Schulz, M., Faust, D., & Klußmann, E. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00023 · Cited by 59 · see citing works

Modulating Protein-Protein Interactions: From Structural Determinants of Binding to Druggability Prediction to Application

Metz, A., Ciglia, E., & Gohlke, H. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651553 · Cited by 57 · see citing works

Establishment of a robust dengue virus NS3–NS5 binding assay for identification of protein–protein interaction inhibitors

Takahashi, H., Takahashi, C., Moreland, N. J., Chang, Y., Sawasaki, T., Ryo, A., Vasudevan, S. G., Suzuki, Y., & Yamamoto, N. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.09.023 · Cited by 55 · see citing works

Improvement on Permeability of Cyclic Peptide/Peptidomimetic: Backbone N-Methylation as A Useful Tool

Li, Y., Li, W., & Xu, Z. (2021) · Marine Drugs · doi:10.3390/md19060311 · Cited by 57 · see citing works

Protein–Peptide Binding Site Detection Using 3D Convolutional Neural Networks

Kozlovskii, I., & Popov, P. A. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00475 · Cited by 51 · see citing works

2P2I HUNTER : a tool for filtering orthosteric protein–protein interaction modulators via a dedicated support vector machine

Hamon, V., Bourgeas, R., Ducrot, P., Théret, I., Xuereb, L., Basse, M. J., Brunel, J. M., Combes, S., Morelli, X., & Roche, P. (2013) · Journal of The Royal Society Interface · doi:10.1098/rsif.2013.0860 · Cited by 46 · see citing works

Protein–protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays

Gul, S., & Hadian, K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.954544 · Cited by 46 · see citing works

Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View

Engin, H., Gürsoy, A., Nussinov, R., & Keskin, Ö. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990066 · Cited by 45 · see citing works

Druggability Assessment of Protein–Protein Interfaces

Wanner, J., Fry, D. C., Peng, Z., & Roberts, J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.156 · Cited by 44 · see citing works

Advancements and challenges in mRNA and ribonucleoprotein-based therapies: From delivery systems to clinical applications

Eftekhari, Z., Zohrabi, H., Oghalaie, A., Ebrahimi, T., Shariati, F. S., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102313 · Cited by 43 · see citing works

Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease

Fiorentini, C., Savoia, P., Savoldi, D., Barbon, A., & Missale, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.01.005 · Cited by 41 · see citing works

Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition

Cooper, C. D. O., Newman, J. A., & Gileadi, O. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130227 · Cited by 42 · see citing works

What Makes a Good Protein–Protein Interaction Stabilizer: Analysis and Application of the Dual-Binding Mechanism

Chen, S., & Zacharias, M. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00003 · Cited by 40 · see citing works

Discovery of a novel B-cell lymphoma 6 (BCL6)–corepressor interaction inhibitor by utilizing structure-based drug design

Yasui, T., Yamamoto, T., Sakai, N., Asano, K., Takai, T., Yoshitomi, Y., Davis, M., Takagi, T., Sakamoto, K., Sogabe, S., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.07.037 · Cited by 39 · see citing works

New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy

Zeng, L., Zhu, Y., Moreno, C. S., & Wan, Y. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.003 · Cited by 37 · see citing works

The phytotoxin fusicoccin differently regulates 14-3-3 proteins association to mode III targets

Paiardini, A., Aducci, P., Cervoni, L., Cutruzzolà, F., Lucente, C. D., Janson, G., Pascarella, S., Rinaldo, S., Visconti, S., & Camoni, L. (2014) · IUBMB Life · doi:10.1002/iub.1239 · Cited by 38 · see citing works

Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides

Feldman, P., & Khanna, R. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.06.057 · Cited by 37 · see citing works

The present and the future of motif-mediated protein–protein interactions

Seo, M., & Kim, P. M. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2018.04.005 · Cited by 37 · see citing works

New Approaches to Difficult Drug Targets: The Phosphatase Story

Lazo, J. S., McQueeney, K. E., & Sharlow, E. R. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217721142 · Cited by 36 · see citing works

Recent Advances on Small-Molecule Survivin Inhibitors

Xiao, M., & Li, W. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150114102146 · Cited by 36 · see citing works

Small-Molecule Inhibitors of the Interaction Between TNF and TNFR

Davis, J. M., & Colangelo, J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.192 · Cited by 35 · see citing works

Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment

Camps-Fajol, C., Cavero, D., Minguillón, J., & Surrallés, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107544 · Cited by 35 · see citing works

Protein–Protein Interaction Modulators for Epigenetic Therapies

(2018) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/bs.apcsb.2017.06.002 · Cited by 31 · see citing works

Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2–p53 interaction

Zheng, G.-H., Shen, J., Zhan, Y.-C., Hong, Y., Xue, S.-T., Wang, Z., Ji, X., & Li, Z. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.05.027 · Cited by 32 · see citing works

Asymmetric Modular Synthesis of a Semirigid Dipeptide Mimetic by Cascade Cycloaddition/Ring Rearrangement and Borohydride Reduction

Pellegrino, S., Contini, A., Gelmi, M. L., Presti, L. L., Soave, R., & Erba, E. (2014) · The Journal of Organic Chemistry · doi:10.1021/jo500237j · Cited by 32 · see citing works

TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation

Song, Y., & Buchwald, P. (2015) · Current Drug Targets · doi:10.2174/1389450116666150223115628 · Cited by 31 · see citing works

2P2Ichem: focused chemical libraries dedicated to orthosteric modulation of protein–protein interactions

Hamon, V., Brunel, J. M., Combes, S., Basse, M. J., Roche, P., & Morelli, X. (2013) · MedChemComm · doi:10.1039/c3md00018d · Cited by 31 · see citing works

Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction

Sun, H., Wang, J., Liu, S., Zhou, X., Dai, L. X., Chen, C., Xu, Q., Wen, X., Cheng, K., Sun, H., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00521 · Cited by 31 · see citing works

Abrogating the Interaction Between p53 and Mortalin (Grp75/HSPA9/mtHsp70) for Cancer Therapy: The Story so far

Elwakeel, A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.879632 · Cited by 32 · see citing works

Drug discovery by targeting the protein–protein interactions involved in autophagy

Xiang, H., Zhou, M., Li, Y., Zhou, L., & Wang, R. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.016 · Cited by 31 · see citing works

Small-Molecule Inhibitors of the CD40–CD40L Costimulatory Protein–Protein Interaction

Chen, J., Song, Y. G., Bojadzic, D., Tamayo, A., Landin, A. M., Blomberg, B. B., & Buchwald, P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01154 · Cited by 31 · see citing works

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond

Ai, Y., Hwang, L., MacKerell, A. D., Melnick, A. M., & Xue, F. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01686 · Cited by 29 · see citing works

Protein-protein interaction inhibitor of SRPKs alters the splicing isoforms of VEGF and inhibits angiogenesis

Li, Q., Zeng, C., Liu, H., Yung, K. W. Y., Chen, C., Xie, Q., Zhang, Y., Wan, S. W. C., Mak, B. S. W., Xia, J., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102423 · Cited by 28 · see citing works

Small‐molecule modulators of the OX 40– OX40 ligand co‐stimulatory protein–protein interaction

Song, Y. G., Margolles‐Clark, E., Bayer, A. L., & Buchwald, P. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12819 · Cited by 28 · see citing works

Mimicking Peptides… In Silico

Floris, M., & Moro, S. (2011) · Molecular Informatics · doi:10.1002/minf.201100093 · Cited by 25 · see citing works

Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models

Zaka, M., Abbasi, B. H., & Durdağı, S. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1491423 · Cited by 26 · see citing works

Targeting platelet inhibition receptors for novel therapies: PECAM-1 and G6b-B

Jerez, E. M. S., Gibbins, J. M., & Hughes, C. E. (2021) · Platelets · doi:10.1080/09537104.2021.1882668 · Cited by 23 · see citing works

Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells

Pallai, R., Bhaskar, A., Barnett-Bernodat, N., Ebert, C., Pusey, M., Nickels, J. T., & Rice, L. M. (2015) · Tumor Biology · doi:10.1007/s13277-015-3326-1 · Cited by 23 · see citing works

The Potential of Peptide-Based Inhibitors in Disrupting Protein–Protein Interactions for Targeted Cancer Therapy

Afonso, A. L., Cavaleiro, C. T., Castanho, M. A. R. B., Neves, V., & Cavaco, M. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073117 · Cited by 23 · see citing works

In Silico Identification and Evaluation of Natural Products as Potential Tumor Necrosis Factor Function Inhibitors Using Advanced Enalos Asclepios KNIME Nodes

Papadopoulou, D., Drakopoulos, A., Lagarias, P. I., Melagraki, G., Kollias, G. A., & Afantitis, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910220 · Cited by 20 · see citing works

Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19

Buchwald, P. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.898035 · Cited by 20 · see citing works

Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell function

Hawley, K. M., Eclov, R. J., Schnorenberg, M. R., Tian, Y. P., Shah, R. N., Thomas-Toth, A. T., Fefferman, M. L., Bird, G. H., Walensky, L. D., Tirrell, M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2209044119 · Cited by 19 · see citing works

3‐Substituted Indazoles as Configurationally Locked 4EGI‐1 Mimetics and Inhibitors of the eIF4E/eIF4G Interaction

Yefidoff‐Freedman, R., Chen, T., Sahoo, R., Chen, L., Wagner, G., Halperin, J. A., Aktas, B. H., & Chorev, M. (2014) · ChemBioChem · doi:10.1002/cbic.201300723 · Cited by 19 · see citing works

Conformational Strain of Macrocyclic Peptides in Ligand–Receptor Complexes Based on Advanced Refinement of Bound-State Conformers

Brueckner, A. C., Deng, Q., Cleves, A. E., Lesburg, C. A., Alvarez, J. C., Reibarkh, M., Sherer, E. C., & Jain, A. N. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02159 · Cited by 18 · see citing works

Advances in the synthesis of glycosidic macrolides: clavosolides A–D and cyanolide A

Lee, K., Lanier, M. L., Kwak, J., Kim, H., & Hong, J. (2016) · Natural Product Reports · doi:10.1039/c6np00073h · Cited by 18 · see citing works

ReLo is a simple and rapid colocalization assay to identify and characterize direct protein–protein interactions

Salgania, H. K., Metz, J., & Jeske, M. (2024) · Nature Communications · doi:10.1038/s41467-024-47233-4 · Cited by 17 · see citing works

Application of Nanopore Sensors for Biomolecular Interactions and Drug Discovery

Jeong, K., Kim, J., Dhanasekar, N. N., Lee, M., & Chi, S. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200679 · Cited by 17 · see citing works

The promiscuous protein binding ability of erythrosine B studied by metachromasy (metachromasia)

Ganesan, L., & Buchwald, P. (2013) · Journal of Molecular Recognition · doi:10.1002/jmr.2263 · Cited by 17 · see citing works

Structural insight into TNF-α inhibitors through combining pharmacophore-based virtual screening and molecular dynamic simulation

Qaiser, H., Saeed, M., Nerukh, D., & Ul‐Haq, Z. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1796794 · Cited by 16 · see citing works

Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway

Harwood, S. J., Smith, C. R., Lawson, J. D., & Ketcham, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087373 · Cited by 16 · see citing works

Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40–CD154 Costimulatory Protein-Protein Interaction

Bojadzic, D., Chen, J., Alcazar, O., & Buchwald, P. (2018) · Molecules · doi:10.3390/molecules23051153 · Cited by 15 · see citing works

In-silico design, pharmacophore-based screening, and molecular docking studies reveal that benzimidazole-1,2,3-triazole hybrids as novel EGFR inhibitors targeting lung cancer

Kumar, S., Ali, I. F. M., Abbas, F., Rana, A., Pandey, S., Garg, M., & Kumar, D. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2252496 · Cited by 14 · see citing works

Computational biology assisted exploration of phytochemicals derived natural inhibitors to block BZLF1 gene activation of Epstein–Bar virus in host

Naveed, M., Hussain, M., Aziz, T. A., Hanif, N., Kanwal, N., Arshad, A., Khan, A. A., Alshammari, A., & Alharbi, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-81037-2 · Cited by 13 · see citing works

Development of Small Molecules to Target the Ige:FcεRi Protein–Protein Interaction in Allergies

Smith, L. D., Leatherbarrow, R. J., & Spivey, A. C. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.112 · Cited by 13 · see citing works

β-Turn mimetic-based stabilizers of protein–protein interactions for the study of the non-canonical roles of leucyl-tRNA synthetase

Kim, C., Jung, J., Tùng, T. T., & Park, S. B. (2015) · Chemical Science · doi:10.1039/c5sc03493k · Cited by 13 · see citing works

Split-Luciferase Complementation Assay to Detect Channel–Protein Interactions in Live Cells

Shavkunov, A. S., Ali, S. R., Panova, N. I., & Laezza, F. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2425-7_33 · Cited by 12 · see citing works

Virtual screening for inhibitors of the human TSLP:TSLPR interaction

Rompaey, D. V., Verstraete, K., Peelman, F., Savvides, S. N., Augustyns, K., der Veken, P. V., & Winter, H. L. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-17620-7 · Cited by 11 · see citing works

In silico exploration of small-molecule α-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2

Hakmi, M., Bouricha, E. M., Akachar, J., Lmimouni, B., Harti, J. E., Belyamani, L., & Ibrahimi, A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1830175 · Cited by 10 · see citing works

Novel anti-PD-L1 peptide selected from combinatorial phage library inhibits tumor cell growth and restores T-cell activity

Tooyserkani, R., Rasaee, M. J., Bandehpour, M., & Löwik, D. W. P. M. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1879087 · Cited by 9 · see citing works

Computational methods for binding site prediction on macromolecules

Kozlovskii, I., & Popov, P. A. (2025) · Quarterly Reviews of Biophysics · doi:10.1017/s003358352500006x · Cited by 8 · see citing works

A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissues

Bergman, D. R., Sweis, R. F., Pearson, A. T., Nazari, F., & Jackson, T. L. (2022) · iScience · doi:10.1016/j.isci.2022.104387 · Cited by 8 · see citing works

Docetaxel as a Model Compound to Promote HDL (High-Density Lipoprotein) Biogenesis and Reduce Atherosclerosis

Choi, H. Y., Iatan, I., Ruel, I. L., Brown, L., Hales, L., Choi, S., & Genest, J. J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318275 · Cited by 8 · see citing works

PPII-AEAT: Prediction of protein-protein interaction inhibitors based on autoencoders with adversarial training

Zhang, Z., Zhao, L., Gao, M., Chen, Y., Wang, J., & Wang, C. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108287 · Cited by 7 · see citing works

Small-molecule inhibitors of the CD40–CD40L costimulatory interaction are effective in pancreatic islet transplantation and prevention of type 1 diabetes models

Chuang, S.-T., Alcazar, O., Watts, B. M., Abdulreda, M. H., & Buchwald, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1484425 · Cited by 7 · see citing works

Integrating Protein Interaction Surface Prediction with a Fragment-Based Drug Design: Automatic Design of New Leads with Fragments on Energy Surfaces

Torielli, L., Serapian, S. A., Mussolin, L., Moroni, E., & Colombo, G. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01408 · Cited by 7 · see citing works

Bioinformatic Identification of Peptidomimetic-Based Inhibitors againstPlasmodium falciparumAntigen AMA1

Alam, A. (2014) · Malaria Research and Treatment · doi:10.1155/2014/642391 · Cited by 7 · see citing works

A general model for predicting the binding affinity of reversibly and irreversibly dimerized ligands

Foreman, K. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188134 · Cited by 7 · see citing works

Comparative Analysis of Cyclization Techniques in Stapled Peptides: Structural Insights into Protein–Protein Interactions in a SARS-CoV-2 Spike RBD/hACE2 Model System

Ferková, S., Froehlich, U., Nepveu-Traversy, M.-É., Murza, A., Azad, T., Grandbois, M., Sarret, P., Lavigne, P., & Boudreault, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010166 · Cited by 6 · see citing works

Small-Molecule Inhibitors of Protein–Protein Interactions as Therapeutics

Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_7 · Cited by 1 · see citing works

Future Frontiers in Small Molecule Inhibitors of Protein-Protein Interactions

Ma, D., Leung, C., & Chan, D. S. (2013) · International Journal of Bioorganic Chemistry & Molecular Biology · doi:10.19070/2332-2756-130002e

Inhibitors of protein–protein interactions (PPIs): an analysis of scaffold choices and buried surface area

Xu, R., & Gestwicki, J. E. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.004 · Cited by 262 · see citing works

Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality

Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065 · see citing works

A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors

Villoutreix, B. O., Labbé, C. M., Lagorce, D., Laconde, G., & Spérandio, O. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651571 · Cited by 68 · see citing works